Apimeds Pharmaceuticals US Income Statement (2023-2025) | APUS

Income Statement Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Operating items
Research & Development (Quarter) 0.65M0.62M0.36M
Selling, General & Administrative (Quarter) 0.27M0.43M0.30M0.28M0.36M2.01M1.22M6.68M
Operating Expenses (Quarter) 0.27M0.43M0.30M0.28M0.36M2.66M1.84M7.04M
Operating Income (Quarter) -0.27M-0.43M-0.30M-0.28M-0.36M-2.66M-1.84M-7.04M
EBIT (Quarter) -0.27M-0.43M-0.30M-0.28M-0.36M-2.66M-1.84M-7.04M
Non-operating items
Interest & Investment Income (Quarter) 0.00M517.00116.0030.003.000.02M0.06M0.04M
Non Operating Income (Quarter) -0.02M-0.02M-0.03M-0.04M-0.04M0.00M0.06M5.88M
Net income details
EBT (Quarter) -0.30M-0.45M-0.33M-0.31M-0.40M-2.67M-1.79M-7.22M
Profit After Tax (Quarter) -0.30M-0.45M-0.33M-0.31M-0.40M-2.66M-1.78M-1.16M
Income from Continuing Operations (Quarter) -0.30M-0.45M-0.33M-0.31M-0.40M-2.67M-1.79M-7.22M
Consolidated Net Income (Quarter) -0.30M-0.45M-0.33M-0.31M-0.40M-2.67M-1.79M-7.22M
Income towards Parent Company (Quarter) -0.30M-0.45M-0.33M-0.31M-0.40M-2.67M-1.79M-7.22M
Net Income towards Common Stockholders (Quarter) -0.30M-0.45M-0.33M-0.31M-0.40M-2.67M-1.79M-7.22M
Additional items
EPS (Basic) (Quarter) -0.04-0.06-0.04-0.04-0.05-0.26-0.14-0.08
EPS (Weighted Average and Diluted) (Quarter) -0.04-0.06-0.04-0.04-0.05-0.26-0.14-0.08
Shares Outstanding (Weighted Average) (Quarter) 4.60M7.90M7.90M7.90M7.90M7.90M10.37M10.31M10.88M
Shares Outstanding (Diluted Average) (Quarter) 7.90M7.90M7.90M7.90M7.90M10.37M12.58M10.88M
EBITDA (Quarter) -0.27M-0.43M-0.30M-0.28M-0.36M-2.66M-1.84M-7.04M
Interest Expenses (Quarter) 0.03M0.02M0.03M0.04M0.04M0.02M0.01M0.22M